Zymeworks Inc. logo ZYME - Zymeworks Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 19
HOLD 2
SELL 0
STRONG
SELL 0
| PRICE TARGET: $40.50 DETAILS
HIGH: $48.00
LOW: $31.00
MEDIAN: $41.50
CONSENSUS: $40.50
UPSIDE: 56.49%

Stock News

Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma

Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma

Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue beyond oncology, enhancing earnings visibility.

Jul 01, 2026 04:30 AM • seekingalpha.com
Zymeworks to Acquire Theravance Biopharma, Inc.

Zymeworks to Acquire Theravance Biopharma, Inc.

VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH); a biopharmaceutical company focused on delivering Medicines that Make a Difference ® in people's lives. This proposed acquisition adds YUPELRI®, the first and only nebulized, once-daily, long-acting muscarinic antagonist (LAMA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD), to Zymeworks' partnered portfolio, furthering the Company's commitment to improving outcomes for patients with serious diseases.

Jun 29, 2026 02:00 AM • globenewswire.com
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

Vancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cryo-EM–based structural data to augment antibody drug discovery. VANCOUVER, BC, June 18, 2026 /PRNewswire/ - Gandeeva Therapeutics, Inc., a biotech at the forefront of cryo-electron microscopy (cryo-EM)–driven drug design, and Zymeworks Inc. (Nasdaq: ZYME), a global biotechnology company, have partnered to visualize structures of antibody-antigen interfaces at high resolution.

Jun 18, 2026 04:00 AM • prnewswire.com
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2026.

Jun 14, 2026 02:05 PM • globenewswire.com
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression level Confirmed objective response rate (cORR) of 78. 6% in FRα-positive (≥75% at PS2) platinum-resistant ovarian cancer patients and 47. 4% in FRα-negative patients (<75% at PS2) across all dose levels studied Median duration of response was not reached at the time of data cutoff, and median progression-free survival was 7.

Jun 14, 2026 02:05 PM • globenewswire.com
Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality

Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality

Zymeworks is transitioning into an oncology royalty platform with a robust internal discovery engine, offering a differentiated risk-reward profile versus traditional biotech peers. ZYME's balance sheet is fortified with over $400 million in liquid assets, a $440 million milestone pipeline, and a $125 million share repurchase program, supporting operations beyond 2028. Zanidatamab's Priority Review for first-line HER2-positive GEA, with a PDUFA date of August 25, 2026, could trigger $265 million in near-term milestone payments and unlock substantial royalty streams.

May 22, 2026 03:30 AM • seekingalpha.com
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a 2026 share repurchase program under which the Company may repurchase up to $125.0 million of its outstanding common stock, par value $0.00001 per share. Concurrently, Zymeworks has terminated its existing 2025 share repurchase program under which the Company has repurchased 4,197,553 million shares of common stock for $102.3 million, representing an average purchase price of $24.36 per common share.

May 14, 2026 12:05 PM • globenewswire.com
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026 China's NMPA has accepted the sBLA for zanidatamab; the U.S. FDA has granted Breakthrough Therapy Designation to zanidatamab in combination with fluoropyrimidine- and platinum-based chemotherapy (±) TEVIMBRA, for this indication. Presented new data from our Phase 1 trial of ZW191 at AACR, continuing to support best-in-class potential in ovarian and endometrial cancers Presented on emerging RAS inhibitor antibody-drug conjugate platform at AACR $95.8 million utilized for share repurchases as of May 6, 2026 under the current authorized share repurchase program Reported $403.8 million in cash, cash equivalents and marketable securities as of March 31, 2026 Conference call with management today at 4:30 p.m.

May 07, 2026 12:05 PM • globenewswire.com
Zymeworks (NASDAQ:ZYME) and ADVANZ PHARMA (OTCMKTS:CXRXF) Financial Contrast

Zymeworks (NASDAQ:ZYME) and ADVANZ PHARMA (OTCMKTS:CXRXF) Financial Contrast

Zymeworks (NASDAQ: ZYME - Get Free Report) and ADVANZ PHARMA (OTCMKTS:CXRXF - Get Free Report) are both manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends. Earnings and Valuation This table compares Zymeworks and ADVANZ

Apr 26, 2026 10:06 PM • defenseworld.net
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera

Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera

Zymeworks (NASDAQ: ZYME) used a presentation at the Bloom Burton conference to outline how the company is repositioning itself around its first approved product and a growing stream of royalty and milestone revenue, while continuing to invest in internal research and development across antibody-drug conjugates (ADCs) and multispecific antibodies. The speaker, who noted it was the

Apr 25, 2026 11:12 PM • defenseworld.net
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced results from the dose-escalation part of the Phase 1 study for ZW191, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

Apr 21, 2026 01:30 PM • globenewswire.com

Price Targets